DrugPatentWatch Database Preview

LAMICTAL XR Drug Profile

« Back to Dashboard

Which patents cover Lamictal Xr, and what generic alternatives are available?

Lamictal Xr is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-three patent family members in thirty-eight countries.

The generic ingredient in LAMICTAL XR is lamotrigine. There are thirty-two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

Summary for LAMICTAL XR

International Patents:	93
US Patents:	2
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	98
Clinical Trials:	63
Patent Applications:	4,186
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for LAMICTAL XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAMICTAL XR
DailyMed Link:	LAMICTAL XR at DailyMed

Pharmacology for LAMICTAL XR

Drug Class	Mood Stabilizer Anti-epileptic Agent
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Synonyms for LAMICTAL XR

1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-

3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine

3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine

3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine

3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine

3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine

57L841

6-(2,2,4-triazine-3,5-diyldiamine

6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine

6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine)

6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine

6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine

6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine

84057-84-1

A840709

AB0014255

AB00384359_17

AB00384359_18

AB00384359-16

AC-10298

AC1L1GWT

AJ-08354

AK-72807

AKOS005561147

AN-35947

ANW-44921

AT-15488

B2249

BC200572

BDBM50031299

BIDD:GT0794

Bio-0056

BR-72807

BW 430C

BW-430C

BW430C

C9H7Cl2N5

CAS-84057-84-1

CCG-100856

CHEBI:6367

CHEMBL741

CPD000058464

Crisomet

CS-2616

CTK8B4406

D00354

D03FLC

DB00555

Desitin Brand of Lamotrigine

DSSTox_CID_3195

DSSTox_GSID_23195

DSSTox_RID_76918

DTXSID2023195

EINECS 281-901-8

EU-0100688

EUR-1048

F2173-0540

Faes Brand of Lamotrigine

FT-0602546

GI 267119X

GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine

Glaxo Wellcome Brand of Lamotrigine

GlaxoSmithKline Brand of Lamotrigine

GTPL2622

GW 273293

HE054180

HE395696

HMS2051C10

HMS2089M08

HMS2093P21

HMS2230L04

HMS3262I17

HMS3268G17

HMS3371O16

HMS3393C10

HMS3657A17

HSDB 7526

HY-B0495

hydroxymethyl progesterone

J10032

Juste Brand of Lamotrigine

K499

KS-00000XIV

KS-1074

L 3791

L0241

Labileno

Lamictal

Lamictal (TN)

Lamictal Cd

Lamictal ODT

Lamictin

Lamictin (TN)

Lamiktal

Lamitor

lamitrin

lamotrigin

Lamotrigina

Lamotrigina [Spanish]

lamotrigine

Lamotrigine (JAN/USAN/INN)

Lamotrigine [USAN:INN:BAN]

Lamotrigine [USAN:USP:INN:BAN]

Lamotrigine 1.0 mg/ml in Methanol

Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard

Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard

Lamotrigine, >=98%, powder

Lamotrigine, European Pharmacopoeia (EP) Reference Standard

Lamotrigine, pharmaceutical secondary standard; traceable to USP and PhEur

Lamotrigine, United States Pharmacopeia (USP) Reference Standard

Lamotriginum

Lamotriginum [Latin]

Lopac-L-3791

Lopac0_000688

LP00688

LS-155249

MCULE-7648410888

MFCD00865333

MLS000069685

MLS000759486

MLS001077325

MLS001423991

MolPort-003-666-744

NC00106

NCGC00015605-01

NCGC00015605-02

NCGC00015605-03

NCGC00015605-04

NCGC00015605-05

NCGC00015605-06

NCGC00015605-07

NCGC00015605-08

NCGC00015605-09

NCGC00015605-10

NCGC00022936-02

NCGC00022936-04

NCGC00022936-05

NCGC00261373-01

NE61394

NSC-746307

NSC-759171

NSC746307

NSC759171

Opera_ID_12

Pharmakon1600-01505610

PYZRQGJRPPTADH-UHFFFAOYSA-N

Q-201221

s3024

SAM001246697

SBI-0050666.P002

SC-12025

SCHEMBL35439

SMP2_000303

SMR000058464

ST24024203

STK628377

Tocris-1611

Tox21_110179

Tox21_110179_1

Tox21_500688

TR-026049

TRI020

U3H27498KS

UNII-U3H27498KS

Z1550648755

ZINC13156

US Patents and Regulatory Information for LAMICTAL XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-001	May 29, 2009	AB	RX	Yes	No			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-004	May 29, 2009	AB	RX	Yes	Yes			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-002	May 29, 2009	AB	RX	Yes	Yes			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-005	Apr 14, 2010	AB	RX	Yes	No			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-004	May 29, 2009	AB	RX	Yes	Yes			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-001	May 29, 2009	AB	RX	Yes	No			Y
Glaxosmithkline Llc	LAMICTAL XR	lamotrigine	TABLET, EXTENDED RELEASE;ORAL	022115-002	May 29, 2009	AB	RX	Yes	Yes			Y

Paragraph IV (Patent) Challenges for LAMICTAL XR

Drugname	Dosage	Strength	RLD	Date
	Extended-release Tablets	25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg

International Patents for LAMICTAL XR

Country	Document Number	Estimated Expiration
Japan	2011057683
Eurasian Patent Organization	008286
South Africa	200500518
China	100363007
African Regional IP Organization (ARIPO)	1736
Canada	2475544
Hong Kong	1072194